WPRIM Management System> DCMS> Acta Pharmaceutica Sinica B> 2018> 8> 4

Volume: 8 Issue: 4

1. Epigenetic modification in histone deacetylase deletion strain of leads to diverse diterpenoids. Page:687—697
2. Biocatalytic access to diverse prenylflavonoids by combining a regiospecific -prenyltransferase and a stereospecific chalcone isomerase. Page:678—686
3. Genome-wide characterization and analysis of bHLH transcription factors in . Page:666—677
4. monitoring of the structural change of microemulsions in simulated gastrointestinal conditions by SAXS and FRET. Page:655—665
5. Authentic compound-free strategy for simultaneous determination of primary coumarins in Peucedani Radix using offline high performance liquid chromatography-nuclear magnetic resonance spectroscopy-tandem mass spectrometry. Page:645—654
6. Limonoids from seeds of A. Juss. and their cytotoxic activity. Page:639—644
7. Synthesis and biological evaluation of novel tricyclic matrinic derivatives as potential anti-filovirus agents. Page:629—638
8. Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Page:615—628
9. Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. Page:602—614
10. Gold nanorods together with HSP inhibitor-VER-155008 micelles for colon cancer mild-temperature photothermal therapy. Page:587—601
11. Garlic-derived compound -allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway. Page:575—586
12. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 and . Page:563—574
13. Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Page:552—562
14. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Page:539—551
15. Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Page:530—538
16. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Page:518—529
17. Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy. Page:511—517
18. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Page:503—510
19. Editorial Preface for Targeted Cancer Therapy. Page:501—502